MRMD Marimed (MRMD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001522767
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
24
Codes C/M, not in net · $0 priced
What the filings say about MRMD
Insiders, 180 days
+$7.8K net bought
1 buyer
Marimed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MARIMED INC. insiders bought a net $7.8K of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on May 20, 2026.
- The trade is 0.2% of the 21,287,986 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Levine Jon R bought about $3.0K of MRMD on May 22, 2026.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on May 20, 2026.
- The trade is 0.0% of the 21,250,986 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Levine Jon R bought about $240 of MRMD on May 22, 2026.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on May 20, 2026.
- The trade is 0.1% of the 21,307,986 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Levine Jon R bought about $1.4K of MRMD on May 22, 2026.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 29, 2024.
- The trade is 0.2% of the 21,247,986 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Levine Jon R bought about $3.2K of MRMD on May 20, 2026.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 29, 2024.
- The trade is 0.5% of the 9,236,770 shares held after it.
- No other insider bought within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Shaw Timothy bought about $5.0K of MRMD on Dec 12, 2025, the largest insider purchase at the company on our record.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$7.8K over 180 days
+$7.8K of it by a 10%+ holder
more than 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+1.3% year over year
below 51% of Pharma & Biotech
Margin
-9.1% net margin
more than 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch MRMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-62.6%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRMD: institutional holders (13F)
13F holdings, latest reported quarter
645,100 sh
$45.2K
Congress trades in MRMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MRMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $7.8K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
MRMD financials
Revenue growth
+1.3%
XBRL, annual
Net margin
-9.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$163.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MRMD
| FY Dec 2025 | $160.0M |
| FY Dec 2024 | $158.0M |
| FY Dec 2023 | $148.6M |
| FY Dec 2022 | $134.0M |
| FY Dec 2021 | $121.5M |
| Jun 2026 | $41.9M |
| Mar 2026 | $39.5M |
| Dec 2025 | $41.6M |
| Sep 2025 | $40.8M |
| Jun 2025 | $39.6M |
| Mar 2025 | $38.0M |
| Dec 2024 | $39.0M |
| Sep 2024 | $40.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-9.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MRMD
| FY Dec 2025 | -9.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -10.8% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +5.9% |
| Jun 2026 | -8.6% |
| Mar 2026 | -9.6% |
| Dec 2025 | -11.1% |
| Sep 2025 | -7.2% |
| Jun 2025 | -3.5% |
| Mar 2025 | -14.5% |
| Dec 2024 | -21.2% |
| Sep 2024 | -2.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$8.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MRMD
| FY Dec 2025 | $6.5M |
| FY Dec 2024 | -$5.2M |
| FY Dec 2023 | -$12.2M |
| FY Dec 2022 | -$4.8M |
| FY Dec 2021 | $18.0M |
| Jun 2026 | $1.9M |
| Mar 2026 | $576.0K |
| Dec 2025 | $3.4M |
| Sep 2025 | $2.1M |
| Jun 2025 | -$12.0K |
| Mar 2025 | $1.0M |
| Dec 2024 | -$1.5M |
| Sep 2024 | -$1.8M |
At each fiscal year end
Single quarter
Debt to equity
2.11x
long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end); equity 2026-06-30
Debt to equity MRMD
| FY Dec 2025 | 1.69x |
| FY Dec 2024 | 1.48x |
| FY Dec 2023 | 0.58x |
| FY Dec 2022 | 0.61x |
| FY Dec 2021 | 0.77x |
| Jun 2026 | 2.11x |
| Mar 2026 | 1.96x |
| Dec 2025 | 1.69x |
| Sep 2025 | 1.56x |
| Jun 2025 | 1.51x |
| Mar 2025 | 1.48x |
| Dec 2024 | 1.48x |
| Sep 2024 | 1.32x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.10x
TTM operating cash flow over long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end)
Cash flow to debt MRMD
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.20x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | 1.29x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.08x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.05x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.06x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-29.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MRMD
| FY Dec 2025 | -26.7% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -25.4% |
| FY Dec 2022 | +28.8% |
| FY Dec 2021 | +32.5% |
| Jun 2026 | -29.9% |
| Mar 2026 | -24.5% |
| Dec 2025 | -26.7% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -19.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-7.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MRMD
| FY Dec 2025 | -7.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -9.2% |
| FY Dec 2022 | +9.8% |
| FY Dec 2021 | +7.2% |
| Jun 2026 | -7.4% |
| Mar 2026 | -6.2% |
| Dec 2025 | -7.1% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MRMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +22.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MRMD
| FY Dec 2025 | -1.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +9.9% |
| FY Dec 2022 | +18.4% |
| FY Dec 2021 | +36.0% |
| Jun 2026 | -1.7% |
| Mar 2026 | -1.2% |
| Dec 2025 | -1.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +4.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MRMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 8.90x |
| FY Dec 2021 | 43.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$106.1M
market value at close 2026-10-27 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end), minus cash 2025-09-30
Enterprise value MRMD
| FY Dec 2025 | $115.1M |
| FY Dec 2024 | $123.6M |
| FY Dec 2023 | $128.5M |
| FY Dec 2022 | $146.1M |
| FY Dec 2021 | $286.3M |
| Jun 2026 | $112.5M |
| Mar 2026 | $111.9M |
| Dec 2025 | $115.1M |
| Sep 2025 | $136.6M |
| Jun 2025 | $106.7M |
| Mar 2025 | $114.6M |
| Dec 2024 | $123.6M |
| Sep 2024 | $143.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+37.1%
TTM free cash flow over market value at close 2026-10-27
FCF yield MRMD
| FY Dec 2025 | +17.6% |
| FY Dec 2024 | -11.7% |
| FY Dec 2023 | -11.8% |
| FY Dec 2022 | -4.0% |
| FY Dec 2021 | +6.2% |
| Jun 2026 | +28.7% |
| Mar 2026 | +22.1% |
| Dec 2025 | +17.6% |
| Sep 2025 | +2.8% |
| Jun 2025 | -8.3% |
| Mar 2025 | -11.1% |
| Dec 2024 | -11.7% |
| Sep 2024 | -8.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MRMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.09x |
| FY Dec 2021 | 0.43x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $159.8M | $158.0M | $148.6M | $134.0M |
| Gross profit | $57.9M | $62.6M | $65.9M | $64.0M |
| Operating income | -$2.8M | $2.6M | $14.4M | $20.4M |
| Net income | -$14.5M | -$12.5M | -$16.0M | $13.5M |
| EPS (diluted) | -0.04 | -0.03 | -0.04 | 0.04 |
| Operating cash flow | $7.7M | $6.8M | $7.9M | $7.3M |
| Cash | n/a | $7.3M | $14.6M | $9.7M |
| Long-term debt | $76.0M | $78.2M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
MRMD Stock Sonar score 5/7 axes
Find similar shapesCompareMRMD ranks highest on profitability (76th percentile) and risk and compliance (73rd), and lowest on financial health (43rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRMD filings, in plain words
Are Marimed insiders buying or selling MRMD?
In the 180 days to 2026-10-28, Marimed insiders were net buyers, a net $7.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Marimed insiders were net buyers of MRMD, a net $7.8K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $7.8K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
